💡 在您使用本产品前请认真阅读说明书,这对您顺利完成实验很有帮助。
|
🏷️ 产品编码
RB9T37015562
|
🧬 中文名称
抗人LIGHT/TNFSF14参考抗体)
|
|
📝 英文名称
Anti-Human LIGHT/TNFSF14 Reference Antibody
| |
|
📦 形态
Liquid
|
🧪 纯度
>95% purity as determined by SDS-PAGE.
|
|
🔹 内毒素水平
Please contact the lab for this information.
| |
|
🔬 应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
| |
|
🧫 表达系统
Mammalian Cells
|
🔢 登录号
O43557
|
|
🔹 宿主种属
Human
|
🔹 克隆性
Monoclonal
|
|
🔹 抗体亚型
IgG4-kappa
|
🔹 纯化方式
Protein A/G purified from cell culture supernatant.
|
|
🔹 浓度
1mg/ml
|
🔹 种属反应性
Human
|
|
🔹 靶标
Herpes virus entry mediator ligand, LIGHT, CD258, HVEM-L, HVEML, TNFSF14, Tumor necrosis factor ligand superfamily member 14, Herpesvirus entry mediator ligand
|
🔹 背景信息
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies.
• LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells., PMID:33606781 • LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells., PMID:27835685 • Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth., PMID:9765287 • A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis., PMID:10318773 |
|
🏷️ 别名
AEVI-002, CERC-002, F-19, MDGN-002, SAR-2520672427667-03-4
| |
🧴 储存缓冲液
0.01M PBS, pH 7.4.
❄️ 稳定性和储存
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
⚠️ For research use only. Not suitable for clinical or therapeutic use.